Patent · US Active

Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases

US10131637B2 · kind B2 · utility

4Cited by

3References

6Claims

0Family size

Assignees

Inventors

Sherin Salaheldin Abdel-Meguid · Exton, US
Magid A. Abou-Gharbia · Wilmington, US
Benjamin E. Blass · Eagleville, US
Wayne E. Childers · New Hope, US
Nabil Elshourbagy · King of Prussia, US
Victor Ghidu · Philadelphia, US
Rogelio L. Martinez · Plainsboro, US
Harold V. Meyers · Lexington, US
Shaker A. Mousa · Wynantskill, US

Key dates

Filing date	Mar 11, 2014
Grant date	Nov 20, 2018
Priority date	—
Expiry date	Mar 11, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07C2602/02
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are compounds of the class of 2-phenylacetamides that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), and methods of using these modulators to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.